Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Danielle Eidenschink

Nurse Practitioner, Family Fargo, ND Nurse Practitioner

NPI 1225627235 CMS profile 10993949

2101 Elm St N, Fargo, ND 58102

Open in the dashboard

General payments

$6,490

78 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Danielle Eidenschink of Fargo, ND is reported in the CMS Open Payments database as having received $6,490 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,185 19
2023 General $2,096 25
2022 General $3,071 27
2021 General $139 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danielle Eidenschink
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Danielle Eidenschink were reported at $0. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Danielle Eidenschink Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $139 $124 $35–$379 $132
2022 $3,071 $141 $44–$430 $149
2023 $2,096 $154 $49–$476 $160
2024 $1,185 $165 $51–$504 $164
2025 $0 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Medtronic, Inc. $5,945 56 payments
  2. Abbott Laboratories $412 15 payments
  3. Shockwave Medical, Inc $47 2 payments
  4. Biotronik Inc. $34 2 payments
  5. Boston Scientific Corporation $33 2 payments
  6. E.R. Squibb & Sons, L.L.C. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Travel and Lodging $4,350 22 payments
  2. Food and Beverage $2,061 53 payments
  3. Education $79 3 payments
Products named General payments · program years 2021–2024
  1. LINQ II $3,129 29 payments
  2. Micra $853 3 payments
  3. ENSITE PRECISION $281 9 payments
  4. EnSite Precision Cardiac Mapping System $86 4 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $47 2 payments
  6. Solia $34 2 payments
  7. BioMonitor $34 2 payments
  8. Rivacor $34 2 payments
  9. Edora $34 2 payments
  10. Acticor $34 2 payments
  11. Other $116 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

977

Median for Nurse Practitioner: 389

Drug cost

$279,221

Median for Nurse Practitioner: $21,885

Branded share of claims

53.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 242 $216,737
Xarelto Rivaroxaban Brand 40 $37,805
Multaq Dronedarone Hcl Brand 11 $8,425
Metoprolol Succinate Generic 132 $2,998
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 84 $2,758
Mexiletine Hcl Generic 39 $2,674
Sotalol Sotalol Hcl Brand 115 $2,492
Amiodarone Hcl Generic 52 $1,220
Flecainide Acetate Generic 12 $611
Tiadylt Er Diltiazem Hcl Brand 15 $572

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$8,268

Medicare's payments for the services billed

Medicare patients

141

Average age 76

Services billed

177

71 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Arthritis 58%
Heart failure 51%
Ischemic heart disease 49%
Diabetes 41%
Chronic kidney disease 40%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in North Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record